Education
About Us
Working with TipRanks
Follow Us
NeoGenomics (NEO)
NASDAQ:NEO
Total Valuation
NeoGenomics has a market cap or net worth of $1.35B. The enterprise value is $1.24B.
Market Cap$1.35B
Enterprise Value$1.24B
Share Statistics
NeoGenomics has 129,387,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding129,387,800
Owned by Insiders1.23%
Owned by Institutions0.16%
Financial Efficiency
NeoGenomics’s return on equity (ROE) is -0.09 and return on invested capital (ROIC) is -5.83%.
Return on Equity (ROE)-0.09
Return on Assets (ROA)-0.05
Return on Invested Capital (ROIC)-5.83%
Return on Capital Employed (ROCE)-0.07
Revenue Per Employee300.26K
Profits Per Employee-35.78K
Employee Count2,200
Asset Turnover0.40
Inventory Turnover13.85
Valuation Ratios
The current PE Ratio of NeoGenomics is ―. NeoGenomics’s PEG ratio is 0.46.
PE Ratio―
PS Ratio0.63
PB Ratio0.46
Price to Fair Value0.46
Price to FCF-12.26
Price to Operating Cash Flow19.54
PEG Ratio0.46
Income Statement
In the last 12 months, NeoGenomics had revenue of 660.57M and earned -78.73M in profits. Earnings per share was -3.10.
Revenue660.57M
Gross Profit290.10M
Operating Income-92.11M
Pretax Income-80.67M
Net Income-78.73M
EBITDA-1.51M
Earnings Per Share (EPS)-3.10
Cash Flow
In the last 12 months, operating cash flow was 13.69M and capital expenditures -30.74M, giving a free cash flow of -17.05M billion.
Operating Cash Flow13.69M
Free Cash Flow-17.05M
Free Cash Flow per Share-0.13
Dividends & Yields
NeoGenomics pays an annual dividend of $0.4, resulting in a dividend yield of ―
Dividend Per Share$0.4
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.24
52-Week Price Change-39.14%
50-Day Moving Average9.15
200-Day Moving Average8.71
Relative Strength Index (RSI)52.71
Average Volume (3m)4.69M
Important Dates
NeoGenomics upcoming earnings date is Feb 25, 2026, TBA (Confirmed).
Last Earnings DateOct 28, 2025
Next Earnings DateFeb 25, 2026
Ex-Dividend DateDec 17, 2020
Financial Position
NeoGenomics as a current ratio of 1.98, with Debt / Equity ratio of 48.95%
Current Ratio1.98
Quick Ratio1.89
Debt to Market Cap1.30
Net Debt to EBITDA-157.72
Interest Coverage Ratio-13.92
Taxes
In the past 12 months, NeoGenomics has paid -1.95M in taxes.
Income Tax-1.95M
Effective Tax Rate0.02
Enterprise Valuation
NeoGenomics EV to EBITDA ratio is -434.01, with an EV/FCF ratio of -19.27.
EV to Sales0.99
EV to EBITDA-434.01
EV to Free Cash Flow-19.27
EV to Operating Cash Flow93.38
Balance Sheet
NeoGenomics has $164.12M in cash and marketable securities with $410.31M in debt, giving a net cash position of -$246.19M billion.
Cash & Marketable Securities$164.12M
Total Debt$410.31M
Net Cash-$246.19M
Net Cash Per Share-$1.90
Tangible Book Value Per Share$1.57
Margins
Gross margin is 43.46%, with operating margin of -13.94%, and net profit margin of -11.92%.
Gross Margin43.46%
Operating Margin-13.94%
Pretax Margin-12.21%
Net Profit Margin-11.92%
EBITDA Margin-0.23%
EBIT Margin-11.21%
Analyst Forecast
The average price target for NeoGenomics is $13.29, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$13.29
Price Target Upside32.90% Upside
Analyst ConsensusModerate Buy
Analyst Count11
Revenue Growth Forecast10.10%
EPS Growth Forecast-44.29%